Medicare drug plans can now cover Eli Lilly & Co.’s obesity drug Zepbound as a treatment for obstructive sleep apnea, news that’s expected to prove a big boost for the drug company.

Medicare drug plans can now cover Eli Lilly's blockbuster obesity drug Zepbound for obstructive sleep apnea, the Centers for Medicare & Medicaid Services confirmed to CNBC. That opens the door for ...

Medicare covers 80% of the cost for a CPAP machine and supplies if you have a specific type of sleep apnea. To get coverage for a CPAP machine, you have to show that you have sleep apnea through a ...

Zepbound (tirzepatide) is a brand-name drug prescribed to help with weight management or obstructive sleep apnea in certain adults. Zepbound comes as a solution for injection under the skin ...

A new study suggests blockbuster weight loss drugs Wegovy and Zepbound are not cost-effective at their current prices, despite the proven health benefits. The study, published in JAMA Health Forum and ...

Eli Lilly has reduced the prices of certain Zepbound vials and introduced higher ... the FDA also green-lit it to treat moderate to severe sleep apnea. How Much Do the Vials Cost Now?

Medicare should cover most types of sleep studies when they are necessary to diagnose sleep apnea. It may also cover certain studies to diagnose other sleep-related conditions. Polysomnographies ...

A popular obesity drug may help treat a dangerous disorder in which people struggle to breathe while they sleep, a new study finds. Tirzepatide, the medication in the weight-loss drug Zepbound and ...

"It's called GLP-1 receptor," said Dr. Atul Malhotra from the UC San Diego School of Medicine. It’s already FDA-approved to ...

This major development ensures that eXciteOSA ® therapy can be more readily accessed by Medicare and Medicaid ... s mission to make root-cause sleep apnea solutions available to patients across ...

Eligible patients diagnosed by a health-care provider with obesity alone or along with obstructive sleep apnea ... to pay for Zepbound themselves and are enrolled in Medicare or employer ...

INDIANAPOLIS (dpa-AFX) - The U.S. Food and Drug Administration approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea or OSA in adults with obesity ...